Radical cystectomy for clinically muscle invasive bladder cancer: Does prior non-invasive disease affect clinical outcomes?

Ahmed F. Kotb, Evan Kovac, Wassim Kassouf, Joe Chin, Yves Fradet, Jonathan Izawa, Eric Estey, Adrian Fairey, Ricardo Rendon, Ilias Cagiannos, Louis Lacombe, Jean Baptiste Lattouf, David Bell, Darrel Drachenberg, Armen G. Aprikian

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Purpose: To compare clinical and pathologic outcomes of radical cystectomy for muscle invasive bladder cancer in relation to prior history of non-invasive urothelial carcinoma. Materials and methods: Retrospective data collected from 1,150 patients managed by radical cystectomy for urothelial carcinoma of the bladder from the Canadian Bladder Cancer Network were analysed. Patients with clinical stage T2 or more were included and divided into two groups: (Group 1) patients with prior history of non-invasive urothelial carcinoma (N = 365) and (Group 2) patients with clinical muscle invasive cancer de novo (N = 785). Variables analysed included patient age, gender, pathologic stage, adjuvant chemotherapy, recurrence and mortality. Results: Both groups were nearly equal in mean age and gender distribution, with mean ages of 67. 2 and 66. 7 years, and 79. 7 and 79. 5%, respectively (P = 0. 4 and 0. 9, respectively). The presence of preoperative hydronephrosis was 20. 8 and 32. 6% (P = 0. 0007) for groups 1 and 2, respectively. The rate of higher pathological stage (T3 or T4) was 36. 3 and 58% (P < 0. 0001), positive lymph nodes were 20. 1 and 28. 8% (P = 0. 002), and lymphovascular invasion was 31. 7 and 46. 2% (P = 0. 0001) for groups 1 and 2, respectively. The rate of adjuvant chemotherapy was 15. 5 and 23. 3% (P = 0. 002) for groups 1 and 2, respectively. None of the sampled patients received neoadjuvant chemotherapy. The overall survival (OS) and disease-specific survival (DSS) rates at 5 years were 62 and 70% for group 1 and 51 and 60% for group 2, respectively, while at 10 years, OS and DSS were 46 and 66% for group 1 and 35 and 49% for group 2, respectively (P = 0. 0001 and 0. 0002, respectively). Using multivariate analysis examining factors affecting recurrence and survival, we found that previous non-invasive bladder tumour history was associated with a significantly reduced risk of mortality and recurrence (Hazard ratio of 0. 7 for all risks, P = 0. 0002). Conclusion: Our retrospective study suggests that patients with non-invasive urothelial carcinoma of the bladder that progress to muscle invasion and require radical cystectomy appear to have better pathologic and clinical outcome than patients presenting with clinical muscle invasive disease de novo.

Original languageEnglish (US)
Pages (from-to)761-767
Number of pages7
JournalWorld Journal of Urology
Volume30
Issue number6
DOIs
StatePublished - Dec 1 2012
Externally publishedYes

Keywords

  • Bladder cancer
  • History
  • Muscle invasive
  • Non-invasive
  • Outcomes
  • Radical cystectomy

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Radical cystectomy for clinically muscle invasive bladder cancer: Does prior non-invasive disease affect clinical outcomes?'. Together they form a unique fingerprint.

  • Cite this

    Kotb, A. F., Kovac, E., Kassouf, W., Chin, J., Fradet, Y., Izawa, J., Estey, E., Fairey, A., Rendon, R., Cagiannos, I., Lacombe, L., Lattouf, J. B., Bell, D., Drachenberg, D., & Aprikian, A. G. (2012). Radical cystectomy for clinically muscle invasive bladder cancer: Does prior non-invasive disease affect clinical outcomes? World Journal of Urology, 30(6), 761-767. https://doi.org/10.1007/s00345-012-0832-2